Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), …

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection Results from the Phase 2b KEYNOTE-942 trial selected for AACR press program Companies…#keytruda #cambridge #rahway #njaccesswire #rna #merck #msd #mrna4157p201 #mrna4157 #rfs

Source: Reuters: Health - April 17, 2023 Category: Consumer Health News Source Type: news